证券代码：300254 证券简称：仟源医药 公告编号：2025-035 山西仟源医药集团股份有限公司 关于 2024 年限制性股票激励计划 第一个解除限售期解除限售条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、符合本次限制性股票解除限售条件的激励对象共计 47 人； 2、本次解除限售数量 268 万股，占目前公司总股本的 1.0792%； 3、本次解除限售的限制性股票在解除限售手续办理完后、上市流通前，公 司将披露限制性股票上市流通的提示性公告，敬请投资者注意。 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 17 日召 开第五届董事会第二十九次会议，审议通过了《关于公司 2024 年限制性股票激 励计划第一个解除限售期解除限售条件成就的议案》，董事会认为公司《2024 年限制性股票激励计划》（以下简称"《激励计划》"）规定的第一个解除限售期 的解除限售条件已经成就，同意按规定为符合条件的 47 名激励对象办理 268 万 股的解锁相关事宜，现将有关事项说明如下： 一、本次激励计划实施情况概要 （ ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-034 山西仟源医药集团股份有限公司 第五届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 14 日 以邮件方式发出第五届董事会第二十九次会议通知及议案，2025 年 7 月 17 日公 司以通讯表决的方式召开本次会议。本次会议由董事长黄乐群先生主持，应出席 董事 8 名，实际出席董事 8 名，出席会议人员对本次会议的召集、召开方式无异 议。本次会议的召集、召开符合《公司法》《公司章程》和《董事会议事规则》的 有关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以投票表决 方式审议通过如下议案： 议案 1：《关于公司 2024 年限制性股票激励计划第一个解除限售期解除限售 条件成就的议案》 公司 2024 年限制性股票激励计划的第一个限售期将于 2025 年 7 月 25 日届 满，根据公司《2024 年限制性股票激励计划》的相关规 ...

Market Overview - The Shanghai Composite Index increased by 0.36% as of the morning close, with a trading volume of 783.11 million shares and a transaction amount of 934.47 billion yuan, a decrease of 3.50% compared to the previous trading day [1] Industry Performance - Real estate, banking, and oil & petrochemicals sectors showed the highest gains, with increases of 1.53%, 1.42%, and 1.23% respectively [1] - The automotive, defense, and electronics sectors experienced the largest declines, with decreases of 0.93%, 0.92%, and 0.76% respectively [2] Leading Stocks - In the real estate sector, Yuhua Development led with a gain of 9.94% [1] - In the banking sector, Minsheng Bank rose by 5.12% [1] - In the oil & petrochemicals sector, *ST Xinchao increased by 5.08% [1] - In the steel sector, Jinling Mining surged by 10.02% [1] - In the non-bank financial sector, Nanhua Futures also rose by 10.02% [1] - In the pharmaceutical sector, Qianyuan Pharmaceutical saw a significant increase of 19.98% [1] Sector Summary - The real estate sector had a transaction amount of 117.03 billion yuan, up 26.74% from the previous day [1] - The banking sector recorded a transaction amount of 266.82 billion yuan, up 36.61% [1] - The oil & petrochemicals sector had a transaction amount of 80.95 billion yuan, up 36.47% [1] - The automotive sector had a transaction amount of 389.36 billion yuan, down 16.50% [2] - The defense sector recorded a transaction amount of 316.85 billion yuan, down 23.79% [2] - The electronics sector had a transaction amount of 1,036.63 billion yuan, down 10.88% [2]

Group 1 - The core viewpoint of the articles highlights the renewed activity in the innovative drug sector, driven by supportive government policies and recent approvals of innovative drugs in the domestic market [1][2] - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, including 16 specific measures across five areas [1] - The introduction of a commercial health insurance directory for innovative drugs aims to include high-value, clinically significant drugs that are not yet part of the basic medical insurance list, indicating a shift towards multi-layered medical insurance systems [1] Group 2 - East China Securities emphasizes the strong policy support for innovative drug development, which is expected to lead to significant growth in the market as new drugs are approved and commercial insurance directories are established [2] - The successful international approval of domestic innovative drugs, such as the approval of Shuwotini by Dize Pharmaceutical in the U.S., showcases the international competitiveness of local innovative drugs [2] - The innovative drug sector is identified as a core investment theme within the biopharmaceutical industry, with recommendations to explore investment opportunities in related segments such as medical devices, traditional Chinese medicine, chain pharmacies, and medical services [2]

Core Viewpoint - QianYuan Pharmaceutical (300254) announced that its subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., received the approval notice for the listing application of Ebastine raw materials from the National Medical Products Administration [1] Group 1: Product Approval - Ebastine is indicated for the symptomatic treatment of allergic rhinitis with or without allergic conjunctivitis and chronic idiopathic urticaria [1] - The original manufacturer of Ebastine is INDUSTRIAS FARMACEUTICAS ALMIRALL, S.A. [1] Group 2: Market Impact - The Ebastine tablets produced by the subsidiary Hangzhou QianYuan BaoLing Pharmaceutical Co., Ltd. have passed the consistency evaluation [1] - Ebastine has been included in the Class B National Medical Insurance Directory, which may enhance its market accessibility [1] Group 3: Cost and Competitiveness - The approval of Ebastine raw materials for market entry is expected to further reduce the production costs of the formulation products [1] - This reduction in costs is anticipated to enhance the market competitiveness of the products [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-033 山西仟源医药集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，山西仟源医药集团股份有限公司（以下简称"公司"）之子公司江苏 嘉逸医药有限公司收到国家药品监督管理局签发的依巴斯汀《化学原料药上市申 请批准通知书》。现将相关情况公告如下： 一、《化学原料药上市申请批准通知书》基本信息 原料药名称：依巴斯汀 剂型：原料药 包装规格：1kg/袋，5kg/袋，10kg/袋 登记号：Y20230001240 化学原料药注册标准编号：YBY64682025 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 生产企业：江苏嘉逸医药有限公司 二、药品研发及市场情况 依巴斯汀适用于伴有或不伴有过敏性结膜炎的过敏性鼻炎（季节性和常年 性），慢性特发性荨麻疹的对症治疗。 依巴斯汀原研为INDUSTRIAS FARMACEUTICAS ALMIRALL, ...

Market Overview - As of June 12, the Shanghai Composite Index closed at 3402.66 points, with a slight increase of 0.34 points, representing a change of 0.01% [1] - The Shenzhen Component Index closed at 10234.33 points, down by 11.69 points, a decrease of 0.11% [1] - The ChiNext Index closed at 2067.15 points, up by 5.29 points, reflecting an increase of 0.26% [1] Trading Activity - A total of 128 A-shares had a turnover rate exceeding 20% on the same day, indicating significant trading activity [1] - Notably, C Haiyang and Zhongke Magnetic had turnover rates exceeding 50%, suggesting a high level of liquidity and interest in these stocks [1] Top Performing Stocks - C Haiyang (603382) had a closing price of 55.97 yuan with a turnover rate of 85.43% and a remarkable increase of 386.70% [1] - Zhongke Magnetic (301141) closed at 68.13 yuan, with a turnover rate of 67.96% and a gain of 3.20% [1] - Yingsite (301622) closed at 97.32 yuan, achieving a turnover rate of 60.53% and a rise of 20.00% [1] - Jiangnan New Materials (603124) closed at 48.20 yuan, with a turnover rate of 57.58% and an increase of 4.83% [1] - Xiongdi Technology (300546) closed at 34.41 yuan, with a turnover rate of 56.64% and a gain of 7.20% [1] Additional Notable Stocks - Kangliyuan (301287) closed at 50.52 yuan, with a turnover rate of 48.58% and a slight decrease of 0.26% [1] - Qingmu Technology (301110) closed at 72.42 yuan, achieving a turnover rate of 46.33% and a rise of 20.00% [1] - Baixinglong (833075) closed at 46.99 yuan, with a turnover rate of 44.54% and an increase of 29.99% [1] - Hengbao Co., Ltd. (002104) closed at 11.82 yuan, with a turnover rate of 44.51% and a gain of 2.34% [1] - Guokang Biochemical (300804) closed at 61.10 yuan, with a turnover rate of 42.76% and a slight increase of 1.08% [1]

Core Viewpoint - The legal opinion letter from Grandall Law Firm confirms that the procedures for the second extraordinary general meeting of shareholders of Shanxi Qianyuan Pharmaceutical Group Co., Ltd. are in compliance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [1][8]. Group 1: Meeting Procedures - The board of directors convened on May 26, 2025, to approve the proposal for the second extraordinary general meeting of shareholders, which is scheduled for June 11, 2025 [4]. - The notice for the meeting was published on May 27, 2025, detailing the meeting's basic information, including the date, location, and voting procedures [4][5]. - The meeting will include both on-site and online voting arrangements for shareholders [5]. Group 2: Attendance and Voting - As of the record date, the total number of shares with voting rights is 248,318,563 [6]. - A total of 108 shareholders and their proxies attended the meeting, representing 31,074,666 shares, which is 12.5140% of the total voting shares [6]. - The qualifications of the attendees were verified and deemed valid according to legal and regulatory requirements [6]. Group 3: Resolutions and Voting Results - The meeting reviewed and voted on several proposals, with the first proposal requiring a special resolution [7]. - The voting results showed that 30,918,846 shares approved the first proposal, and 30,887,546 shares approved the second proposal, indicating a strong majority [7]. - The voting procedures were conducted in accordance with legal requirements, and the results were confirmed as valid [8].

Meeting Details - The meeting was held on June 11, 2025, at 3:00 PM [1] - Shareholders could vote through both on-site and online methods during specified time slots on the same day [1] Attendance Overview - A total of 108 shareholders attended, representing 31,074,666 shares, which is 12.5140% of the total voting shares [1] - Among them, 17 shareholders attended in person, representing 29,096,686 shares (11.7175%), while 91 shareholders voted online, representing 1,977,980 shares (0.7965%) [1] Minority Shareholders Attendance - 107 minority shareholders participated, representing 17,372,774 shares, which is 6.9962% of the total voting shares [2] - Specifically, 16 minority shareholders attended in person, representing 15,394,794 shares (6.1996%), and 91 voted online, representing 1,977,980 shares (0.7965%) [2] Voting Results - The meeting adopted a combination of on-site and online voting methods [2] - Total votes showed 30,918,846 shares in favor, accounting for 99.4986% of the valid votes cast [2] - There were 101,820 shares against (0.3277%) and a small percentage of abstentions (0.1738%) [2] Minority Shareholders Voting Results - Minority shareholders voted with 17,216,954 shares in favor, which is 0.5861% of the total minority voting shares [3] - Abstentions from minority shareholders totaled 54,000 shares, representing 0.3108% [3] Legal Opinion - The company engaged legal representatives to witness the meeting and confirm that the procedures followed were in compliance with relevant laws and regulations [4] - The legal opinion stated that the meeting's convening, attendance, voting procedures, and results were all valid and lawful [4]

国浩律师（上海）事务所 关于 山西仟源医药集团股份有限公司 2025 年第二次临时股东会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: (+86)(21) 5234 1668 传真/Fax: (+86)(21) 5234 1670 网址/Website: http://www.grandall.com.cn 二〇二五年六月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于山西仟源医药集团股份有限公司 2025 年第二次临时股东会 之 法律意见书 致：山西仟源医药集团股份有限公司 作为具有从事中国法律业务资格的律师事务所，国浩律师（上海）事务所（以 下简称"本所"）接受山西仟源医药集团股份有限公司（以下简称"公司"）的委托， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）等法律法规及规范性文件的规定，指派本所 律师 ...